fusidic acid has been researched along with metoclopramide in 3 studies
| Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (metoclopramide) | Trials (metoclopramide) | Recent Studies (post-2010) (metoclopramide) |
|---|---|---|---|---|---|
| 1,742 | 117 | 344 | 5,044 | 1,216 | 623 |
| Protein | Taxonomy | fusidic acid (IC50) | metoclopramide (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.383 | |
| Myeloperoxidase | Homo sapiens (human) | 0.35 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.721 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.127 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 7.8 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 3.675 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.383 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 7.8 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.2 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.88 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.63 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6237 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.88 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
3 other study(ies) available for fusidic acid and metoclopramide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |